Same Indication

Ipilimumab vs Liraglutide

Ipilimumab vs Liraglutide: Overview

This comparison examines the pharmacological differences between Ipilimumab and Liraglutide.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Liraglutide: GLP-1 receptor agonist enhancing insulin secretion.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Liraglutide — 13 hours.

Chemical Properties

Type: Ipilimumab — Antibody; Liraglutide — Protein.